Basic Research in Cardiology

, Volume 83, Issue 6, pp 597–601 | Cite as

Beneficial effect of PGI2 on circulating endothelial cells

  • H. Sinzinger
  • F. Rauscha
  • P. Fitscha
  • J. Kaliman
Original Contributions


Endothelial damage is an early event in atherogenesis. Recent data present evidence that the counting of circulating endothelial cells in human peripheral blood may provide reliable information about endothelial integrity. We therefore assessed the influence of PGI2 on the number of circulating endothelial cells in patients suffering from peripheral vascular disease. As cigarette smokers and patients with hyperlipoproteinemia show an increased number of circulating endothelial cells, they were excluded from this investigation. PGI2 causes a certain drop in circulating endothelial cells. In parallel, a prolongation in platelet half-life can be noted. This is most pronounced at a daily duration of infusion between 4 an 12 h. A shorter duration of PGI2 therapy is less effective in reducing circulating endothelial cells. All of the three different doses used, however, were equally effective. Placebo controls were ineffective. These findings indicate that PGI2 might exert a rather long-lasting beneficial action on endothelial integrity and the hemostatic balance.

Key words

circulatingendothelial cells atherosclerosis prostaglandinI2 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Buchanan MR, Bastida E, Aznar-Salatti J, deGroot P (1987) Is the endothelial extracellular matrix thrombogenic or thromboresistant? Effect of preparation and 13-HODE levels. Thromb Haemost 58:206Google Scholar
  2. 2.
    Davis JW, Shelton L, Eigenberg DA, Hignite CE, Watanabe IS (1985) Comparison of tobacco and non-tobacco cigarette smoking on endothelium and platelets. Clin Pharmacol Ther 37:529–533PubMedGoogle Scholar
  3. 3.
    Davis JW, Shelton L, Eigenberg DA, Hignite CE (1987) Lack of effect of aspirin on cigarette smoke-induced increase in circulating endothelial cells. Haemostasis 7:66–69Google Scholar
  4. 4.
    Fritz E, Ludwig H, Scheithauer W, Sinzinger H (1986) Shortened platelet half-life in multiple myeloma. Blood 68:514–520PubMedGoogle Scholar
  5. 5.
    Hladovec J, Rossmann P (1973) Circulating endothelial cells isolated together with platelets and the experimental modification of their counts in rats. Thromb Res 3:665–674CrossRefGoogle Scholar
  6. 6.
    Hladovec J (1977) Vasotropic drugs—a survey based on a unifying concept of their mechanism of action. Arzneimittel-Forsch 27:1073–1076Google Scholar
  7. 7.
    Hladovec J (1978) Endothelial injury by nicotine and its prevention. Experientia 34:1585–1886PubMedGoogle Scholar
  8. 8.
    Hladovec J (1978) Circulating endothelial cells as a sign of vessel wall lesions. Physiologia bohemoslav 27:140–144Google Scholar
  9. 9.
    McCollum CN, Hawker RJ, Norcott HC, Hail C, Drolc Z, Miller MR (1981) Postoperative platelet accumulation in the lungs: can it be measured in surgical patients and does it matter? Thromb Haemost 46:18Google Scholar
  10. 10.
    Moncada S, Gryglewski RJ, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663–665PubMedGoogle Scholar
  11. 11.
    Mustard JF (1984) Platelets, endothelium and vessel injury. Platelets, Prostaglandin and Cardiovascular Systems. Florence, pp 8–11Google Scholar
  12. 12.
    Prerovsky I, Hladovec J (1979) Suppression of the desquamating effect of smoking on the human endothelium by hydroxyethylrutosides. Blood Vessels 16:239–240PubMedGoogle Scholar
  13. 13.
    Sinzinger, H, O'Grady J, Cromwell M, Höfer R (1983) Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic grafts. Lancet II: 1275–1276CrossRefGoogle Scholar
  14. 14.
    Sinzinger H, Fitscha P (1984) Epoprostenol and platelet deposition in atherosclerosis. Lancet I: 905–906CrossRefGoogle Scholar
  15. 15.
    Sinzinger H, Kolbe H, Strobl-Jäger E, Höfer R (1984) A simple and safe technique for sterile autologous platelet labeling using Monovette-vials. Europ J Nucl Med 9:320–322Google Scholar
  16. 16.
    Sinzinger H, Fitscha P (1986) The principles and applications of treatment of atherosclerotic lesions with prostaglandins. In: Heyns Adu P (Ed) Applications in Atherosclerosis and Thrombosis. South African Medical Research Council, pp 153–162Google Scholar
  17. 17.
    Sinzinger H, Fitscha P (1988) Monitoring of antithrombotic therapy with radiolabeled platelets. Proc Book, Cologne (in press)Google Scholar
  18. 18.
    Thakur ML, Welch MJ, Joist JH (1976) Indium-111-labeled platelets: Studies on preparation and evaluation of in vitro and in vivo function. Thromb Res 9:345–357PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag 1988

Authors and Affiliations

  • H. Sinzinger
    • 1
    • 2
  • F. Rauscha
    • 1
    • 2
  • P. Fitscha
    • 1
    • 2
  • J. Kaliman
    • 1
    • 2
  1. 1.Atherosclerosis Research Group (ASF) Vienna, Atherosclerosis and Thrombosis Research Group (ATK) of the Austrian Academy of Sciences, Depts. of Nuclear Medicine and CardiologyUniversity of Vienna, Ludwig Boltzmann Institute of Nuclear Medicine, ViennaViennaAustria
  2. 2.2nd Dept. of Internal Medicine, PoliclinicViennaAustria

Personalised recommendations